Literature DB >> 2865691

Involvement of hypothalamic somatostatin in the suppression of growth hormone secretion by central corticotropin-releasing factor in conscious male rats.

H Katakami, A Arimura, L A Frohman.   

Abstract

The role of central corticotropin-releasing factor (CRF) in the regulation growth hormone (GH) secretion was studied in freely moving conscious male rats with indwelling intra-atrial and intracerebroventricular (i.c.v.) cannulae. GH measurements in blood samples obtained every 20 min from 10.00 to 14.00 h in control animals injected with saline either intravenously (i.v.) or into the lateral cerebral ventricle revealed that spontaneous GH secretion was pulsatile, and occurred regularly at around 12.00 h. When ovine CRF (10 micrograms) was injected i.c.v., spontaneous GH secretion was inhibited (mean plasma GH [11.20-13.00 h]: 20 +/- 7 ng/ml vs. control: 126 +/- 22 ng/ml, p less than 0.01). In contrast, the intravenous injection of CRF (10 micrograms) did not affect spontaneous GH secretion (mean plasma GH [11.20-13.00 h]: 162 +/- 25 ng/ml vs. control: 193 +/- 31 ng/ml). This GH suppressive action of central CRF was blocked by the i.v. injection (0.5 ml) of antisomatostatin serum (AS), but not of normal sheep serum (NS), (mean plasma GH [11.20-13.00 h]: NS + CRF: 15 +/- 2 ng/ml vs. AS + CRF: 202 +/- 30 ng/ml, p less than 0.01). The mean plasma GH value [11.20-13.00 h] in animals receiving AS and CRF was not significantly different from those in animals receiving saline (i.v.) together with AS. These results suggest a potential inhibitory role of central CRF in the regulation of spontaneous GH secretion in the rat which is mediated by the stimulation of hypothalamic somatostatin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2865691     DOI: 10.1159/000124207

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  11 in total

1.  Effect of corticotropin releasing factor injected into the median eminence on growth hormone secretion in male rats.

Authors:  J Frias; E Ruiz; E Ortega
Journal:  Neurochem Res       Date:  1999-06       Impact factor: 3.996

2.  Gene-environment interactions, not neonatal growth hormone deficiency, time puberty in female rhesus monkeys.

Authors:  Mark E Wilson; Becky Kinkead
Journal:  Biol Reprod       Date:  2007-12-26       Impact factor: 4.285

3.  Effect of CRF injected into the median eminence on GH secretion in female rats under different steroid status.

Authors:  A Puertas; J Frias; E Ruiz; E Ortega
Journal:  Neurochem Res       Date:  1996-08       Impact factor: 3.996

4.  Rapid and opposite effects of dexamethasone on in vivo and in vitro hypothalamic somatostatin release.

Authors:  C Estupina; J Belmar; L Tapia-Arancibia; H Astier; S Arancibia
Journal:  Exp Brain Res       Date:  1997-02       Impact factor: 1.972

5.  The influence of human corticotropin-releasing hormone on somatostatin secretion in depressed patients and controls.

Authors:  K P Lesch; E Widerlöv; R Ekman; G Laux; R Rupprecht; H M Schulte; H Beckmann
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

Review 6.  Adult growth hormone deficiency in patients with fibromyalgia.

Authors:  Robert M Bennett
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

Review 7.  Growth hormone in musculoskeletal pain states.

Authors:  Robert Bennett
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

Review 8.  Modulation of the adaptive response to stress by brain activation of selective somatostatin receptor subtypes.

Authors:  Andreas Stengel; Jean Rivier; Yvette Taché
Journal:  Peptides       Date:  2012-12-31       Impact factor: 3.750

Review 9.  Psychoneuroendocrine research in depression. II. Hormonal responses to releasing hormones as a probe for hypothalamic-pituitary-endorgan dysfunction.

Authors:  K P Lesch; R Rupprecht
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

Review 10.  Central actions of somatostatin-28 and oligosomatostatin agonists to prevent components of the endocrine, autonomic and visceral responses to stress through interaction with different somatostatin receptor subtypes.

Authors:  Andreas Stengel; Jean Rivier; Yvette Taché
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.